FIELD: chemistry.
SUBSTANCE: invention relates to compounds of general formula III 
and their pharmaceutically acceptable salts, A represents (C1-C6)alkyl-O-, phenyl-(C1-C6)alkyl-O-; aryl, selected from phenyl, naphthyl, 
and 
which is possibly substituted by 1-3 substituents, given in the invention formula; or heteroaryl, which has four or five carbon atoms and one heteroatom, selected from oxygen, nitrogen and sulphur, which is possibly substituted by 1-3 substituents, given in the invention formula; B represents phenyl, possibly substituted by 1-3 substituents, where substituents are selected from (C1-C6)alkyl, (C3-C7)cycloalkyl, (C1-C6)alkyl-O-, hydroxy, amino and halogeno; and R1 and R2 independently represent (C1-C6)alkyl, phenyl-(C1-C6)alkyl-, hydroxy-(C1-C6)alkyl, (C3-C7)cycloalkyl, (C2-C6)alkenyl or (C2-C6)alkynyl; on condition that R1 is different from R2; where absolute configuration of asymmetric R1 and R2 -carrying carbon atom is mainly R-configuration. Invention also relates to pharmaceutical composition, possessing ability to modulate gene expression, methods of modulation of gene expression in host cell, method of regulating expression of endogenous or heterologous gene in transgenic subject, method of regulating transgenic expression in transgenic subject, method of polypeptide production and to method of obtaining formula IV 
compound. Method includes stages: a) interaction of formula V compound with formula IV compound with obtaining formula VII compound; b) reduction of formula VII compound with obtaining formula VIII compound, b) interaction of formula VIII compound with formula B-CO-LG compound, where B has values, given above, and LG is leaving group representing -F, -Cl or -Br, with formation of formula IX compound, d) removal of group R7CO2- from formula IX compound with obtaining formula X compound, e) interaction of formula X compound with formula A-CO-LG compound, where A has values, given above, and LG is leaving group, representing -F, -Cl or -Br, with obtaining formula IV compound ( compounds of formulas V, VI, VII, VIII, IX, X are given in the invention formula).
EFFECT: obtaining formula III compounds, possessing ability to modulate gene expression.
19 cl, 4 ex, 2 tbl, 78 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIRAL DIACYLHYDRAZINE LIGANDS FOR MODULATION OF EXOGENOUS GENES EXPRESSION BY ECDYSONE-RECEPTOR COMPLEX | 2013 |
|
RU2640807C2 |
| NOVEL PHARMACEUTICAL USE OF THIENO[3,2-D]PYRIMIDIN-4-ONE COMPOUNDS | 2019 |
|
RU2768828C1 |
| DERIVATIVES OF N-SUBSTITUTED INDOLE-3-GLYOXYLAMIDE AS ANTITUMOR MEDICINAL AGENT AND AGENT INHIBITING ANGIOGENESIS (VARIANTS) AND ANTITUMOR MEDICINAL AGENT (VARIANTS) | 2000 |
|
RU2282444C2 |
| 2,5,7-SUBSTITUTED OXAZOLPYRIMIDINE DERIVATIVES | 2011 |
|
RU2557246C2 |
| PRODRUG 1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | 2003 |
|
RU2357962C2 |
| 5-SULPHANYL-4H-1,2,4-TRIAZOLE DERIVATIVE AND THEIR USE AS MEDICINAL AGENTS | 2002 |
|
RU2367655C2 |
| CYTOTOXIC AND ANTIMITOTIC COMPOUNDS AND METHODS OF USING THEM | 2015 |
|
RU2723651C2 |
| FIVE-MEMBERED HETEROCYCLES AS INHIBITORS OF LEUKOCYTE ADHESION AND VLA-4 ANTAGONISTS | 1997 |
|
RU2229296C2 |
| IMIDAZOPYRIMIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2691629C1 |
| TRIAZOLOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2677698C1 |
